Cutler Group LP Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$40.88 - $43.27 $421,064 - $445,681	-10,300 Reduced 75.74%	3,300 $1,000
Q4 2023 Jan 18, 2024	BUY	$20.27 - $42.44 $275,672 - $577,184	13,600 New	13,600 $107,000
Q1 2023 May 01, 2023	SELL	$22.82 - $35.32 $47,922 - $74,172	-2,100 Reduced 63.64%	1,200 $0
Q4 2022 Feb 07, 2023	BUY	$25.35 - $31.96 $30,420 - $38,352	1,200 Added 57.14%	3,300 $5,000
Q3 2022 Oct 25, 2022	BUY	$25.5 - $41.42 $53,550 - $86,982	2,100 New	2,100 $2,000
Q1 2022 Apr 14, 2022	BUY	$23.5 - $35.38 $359,550 - $541,314	15,300 Added 273.21%	20,900 $47,000
Q4 2021 Jan 18, 2022	SELL	$29.21 - $44.64 $131,445 - $200,880	-4,500 Reduced 44.55%	5,600 $13,000
Q3 2021 Oct 26, 2021	SELL	$21.26 - $38.85 $374,176 - $683,760	-17,600 Reduced 63.54%	10,100 $33,000
Q2 2021 Jul 19, 2021	BUY	$12.56 - $29.69 $347,912 - $822,413	27,700 New	27,700 $91,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.